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In this issue of Cancer Cell, Mason and colleagues describe the development of a Polo-like kinase 4 (PLK4)
inhibitor (CFI-400945), with promising activity against tumors formed in mice from patient-derived tumor
tissue. A clinical trial has been initiated, but questions remain as to whether PLK4 is the only relevant thera-
peutic target.Protein kinases are prime targets for can-
cer therapeutics due to their druggability
and central role in cellular growth path-
ways. Reporting in this issue of Cancer
Cell, Mason et al. (2014) perform a small
interfering RNA (siRNA) screen for kinases
and related genes whose reduction sup-
presses the proliferation of breast cancer
or immortalized cell lines in vitro. One
candidate that emerged was Polo-like
kinase 4 (PLK4). Suppression of PLK4
levels by siRNA significantly reduced
cellular proliferation in about half of the
breast cancer cell lines tested, fueling a
screen for novel PLK4 inhibitors that iden-
tified a potent ATP competitive inhibitor
known as CFI-400945.
PLK4 activity is essential for duplication
of the centrosome, the cell’s major micro-
tubule organizing center (Nigg and Raff,
2009). Centrosomes are present as a sin-
gle copy at the beginning of the cycle
and duplicate once during S phase,
thereby yielding precisely two copies,
each of which becomes a spindle pole
in mitosis (Figure 1A). At the core of the
centrosome lies a pair of centrioles that
acts as the centrosome organizer, and
tight regulation of their replication controls
centrosome duplication (Nigg and Raff,
2009). PLK4 has emerged as a central
regulator of centriole duplication. Sup-
pression of PLK4 levels causes a failure
of centriole and centrosome duplication,
whereas overexpression leads to super-
numary centrioles, a feature sufficient to
drive centrosome amplification and sub-
sequent genome instability.
Although sequencing of cancer cell ge-
nomes has not revealed recurrent/driver
mutations in PLK4, both increased anddecreased expression of the kinase have
been reported in a variety of tumor types.
Although the significance of these expres-
sion changes remains untested, PLK4
heterozygous mice are predisposed to
tumorigenesis (Ko et al., 2005), and over-
expression of PLK4 in Drosophila neuro-
blasts promotes transformation (Basto
et al., 2008). These observations have
made the identification of a selective
PLK4 inhibitor highly desirable, both as a
potential therapeutic agent and for the
dissection of the function(s) of this kinase.
PLK4 is a low abundance enzyme
that phosphorylates itself to promote its
own destruction (Figure 1E). This self-
regulation occurs through the formation
of PLK4 homodimers that trans-auto-
phosphorylate a conserved phospho-
degron to target the kinase for proteaso-
mal degradation (Figure 1F) (reviewed in
Zitouni et al., 2014). As anticipated, com-
plete inhibition of PLK4 with CFI-400945
led to an increase in PLK4 abundance
and a failure of centriole duplication
(Mason et al., 2014). Unexpectedly, how-
ever, lower doses of CFI-400945 drove
the opposite: an increase in centriole
number.
The bimodal effect of CFI-400945 con-
centration on centriole number is surpris-
ing. However, stable overexpression of a
kinase inactive PLK4 in the presence of
the endogenous protein causes centriole
overduplication (Guderian et al., 2010).
This situation is thought to arise from
the formation of heterodimers between
catalytically active and inactive mono-
mers of PLK4. Under these conditions,
kinase inactive PLK4 is unable to trans-
autophosphorylate and destabilize wild-Cancer Cell 26type PLK4, leading to an increase in the
abundance of the wild-type kinase that
results in centriole overduplication. It is
plausible that doses of CFI-400945 that
partially inhibit PLK4 activity generate
mixed heterodimers in which active
PLK4 is stabilized, thereby increasing
overall kinase activity (Figure 1G).
Mason et al. (2014) examined the long-
term effect of CFI-400945 in a wide panel
of breast cancer cell lines. PLK4 mRNA
levels were elevated in breast cancer
cell lines relative to nontransformed cells.
Nevertheless, the level of PLK4 expres-
sion was not predictive of CFI-400945
sensitivity, and thus it remains unclear
whether alterations in PLK4 levels are
causal events in tumor initiation or pro-
gression. More surprisingly, cell lines that
showed the greatest reduction in growth
after PLK4 depletion by siRNA were
among the most resistant to the growth
inhibition produced by CFI-400945. One
explanation is that loss of PLK4 protein
and inhibition of PLK4 kinase activity
have different effects on cellular growth.
An alternative possibility is that the cyto-
static effect of CFI-400945 is caused, at
least in part, by the inhibition of targets in
addition to PLK4 (see below).
A synthetic interaction screen previ-
ously reported that PTEN deficient breast
cancer cell lines are particularly sensitized
to PLK4 depletion (Brough et al., 2011).
Consistently, Mason et al. (2014) report
that loss of the tumor suppressor PTEN
increases sensitivity to CFI-400945.
Given that several of the breast cancer
cell lines tested are relatively resistant to
CFI-400945 in vitro, it will be important
to establish the genetic lesions that confer, August 11, 2014 ª2014 Elsevier Inc. 151
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tumors may be preselected.
Testing of CFI-400945 in mice showed
this agent to be well tolerated with effi-
cient antitumor activity in both cancer
cell lines and patient derived xenograft tu-
mors, including tumors derived from car-
boplatin resistant primary human breast
cancers. This promising discovery has
led to CFI-400945 entering phase I clinical
trials. While the preclinical studies provide
optimism for the use of CFI-400945 as a
novel anticancer therapy, some caution
would also be advised. A first consider-
ation here are the well documented limita-
tions of using xenograft models to predict
a clinical response, with several drugs
that show dramatic tumor killing in xeno-
graft models failing to yield clinical bene-
fits (Sharpless and Depinho, 2006).
Additionally, it remains unclear if PLK4 is
the only, or primary, therapeutic target of
CFI-400945.All kinasesshareasimilar cat-
alytic core, and achieving target specificity
with ATP competitive inhibitors remains
challenging. PLK4 is the most divergent
member of the Polo-like kinase family,
and, correspondingly, CFI-400945 had no
inhibitory activity toward Polo-like kinases
1–3. Nevertheless, CFI-400945 had signif-
icant inhibitory activity toward several
other kinases, including Aurora B both
in vitro and in cells (Mason et al.,
2014).Consistently, CFI-400945 treatment
accompanied by partial or complete PLK4
inhibition led tocytokinesis failureandsub-
sequent polyploidization (Figures 1B and
1C). This outcome is what would be ex-
pected for inhibition of Aurora B (Keen
and Taylor, 2009), which has been well
documented to result in rapid progressionFigure 1. Effect of PLK4 or Aurora B Inhibition
(A) Unperturbed growth. At the beginning of the cell cy
next to each existing centriole (green). The two pairs of
which chromosomes are segregated. Like chromosom
undergoes disengagement in G1 to ‘‘license’’ centriol
(B) Partial PLK4 inhibition. Partial inhibition of PLK4 le
centrioles remain cohesed as functional units and ena
gagement, leading to the creation of multiple centrosom
errors.
(C) Complete PLK4 inhibition. Complete inhibition of P
single centriole at each pole. In the second cell cycle, a
in the formation of an aberrant mitotic spindle that ca
(D) Aurora B inhibition. Aurora B inhibition causes rapi
normal number of chromosomes and centrosomes. S
(E) PLK4 forms homodimers with two molecules phos
bility under direct control of its own activity (Holland e
(F) Treatment with high doses of CFI-400945 (CFI) inhi
and an increase in PLK4 abundance.
(G) Low doses of CFI-400945 generate heterodimers o
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and a corresponding increase in centro-
some number (Figure 1D). Given that
Aurora B inhibitors exhibit excellent anti-
tumor activity in xenografts of human tu-
mor cell lines (and some are now in clinical
evaluation) (Keen and Taylor, 2009), it
seems likely that inhibition of Aurora B is
at least partly responsible for the therapeu-
tic response to CFI-400945. Perhaps inhi-
bition of PLK4 and Aurora B will prove to
be a particularly efficacious anticancer
strategy.
PLK4 is a highly unusual therapeutic
target in as much as partial inhibition of ki-
nase activity leads to a phenotype consis-
tent with increased protein function. This
highlights a dichotomy when using PLK4
inhibitors therapeutically. Depending on
the effective dose achieved in the tumor,
PLK4 inhibitors could partially inhibit
PLK4, resulting in centrosome amplifica-
tion, or completely inhibit PLK4 and pro-
mote centrosome loss (Figures 1F and
1G). Because centrosome amplification
has been linked with tumorigenesis, the
in vivo consequence(s) of using PLK4 in-
hibitors may vary with the degree of target
inhibition.
In summary, CFI-400945 is the first
potent PLK4 inhibitor to be described,
and experiments in mice indicate this
agent may be a useful oncology drug.
However, the inhibition of Aurora B by
CFI-400945 complicates the understand-
ing of the drug’s mechanism of action
(Mason et al., 2014). Recognizing that,
the question of whether inhibition of
PLK4 alone is a valuable therapeutic strat-
egy will have to await the development of
additional PLK4 kinase inhibitors.on Centriole Number
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